Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
Carrie Wynn, Shou‐Ching Tang
Cancer and Metastasis Reviews (2022) Vol. 41, Iss. 1, pp. 193-209
Open Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Biomarkers in Breast Cancer: An Old Story with a New End
Lyvia Neves Rebello Alves, Débora Dummer Meira, Luiza Poppe Merigueti, et al.
Genes (2023) Vol. 14, Iss. 7, pp. 1364-1364
Open Access | Times Cited: 50
Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice
Laura López-González, Alicia Sánchez Cendra, Cristina Sánchez Cendra, et al.
Medicina (2024) Vol. 60, Iss. 1, pp. 168-168
Open Access | Times Cited: 15
Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer
Zohreh Najminejad, Fatemeh Dehghani, Yousef Mirzaei, et al.
Molecular Therapy (2023) Vol. 31, Iss. 7, pp. 1874-1903
Open Access | Times Cited: 37
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
Fei Ma, Min Yan, Wěi Li, et al.
BMJ (2023), pp. e076065-e076065
Open Access | Times Cited: 37
Safety Profile of the Trastuzumab-Based ADCs: Analysis of Real-World Data Registered in EudraVigilance
Claudiu Morgovan, Carmen Maximiliana Dobrea, Anca Butucă, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 953-953
Open Access | Times Cited: 8
Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer
Feifei Li, Sheng Liu
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 33
Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model
Negar Pourjamal, Narjes Yazdi, A. Halme, et al.
Clinical & Experimental Metastasis (2024) Vol. 41, Iss. 2, pp. 91-102
Open Access | Times Cited: 7
PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer
Hongyan Zhang, Longlong Zhang, Yuna He, et al.
Cancer Letters (2024) Vol. 598, pp. 217112-217112
Closed Access | Times Cited: 6
Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies
Jun He, Xianghua Zeng, Chunmei Wang, et al.
MedComm (2024) Vol. 5, Iss. 8
Open Access | Times Cited: 5
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial
Alicia Okines, Giuseppe Curigliano, Nobumasa Mizuno, et al.
Nature Medicine (2025)
Open Access
Anti-apoptotic and antioxidant mechanisms may underlie the abrogative potential of Ocimum gratissimum Linn. Leaf extract and fractions against trastuzumab-induced cardiotoxicity in Wistar rats
Olufunke E. Olorundare, Adejuwon Adewale Adeneye, Akinyele Olubiyi Akinsola, et al.
Toxicology Reports (2024) Vol. 12, pp. 200-214
Open Access | Times Cited: 4
Preparation, Characterization, and Radiolabeling of Anti‐HER2 scFv With Technetium Tricarbonyl and Stability Studies
Negar Bozorgchami, Maryam Ahmadzadeh, Dara Hatamabadi, et al.
Journal of Labelled Compounds and Radiopharmaceuticals (2024) Vol. 67, Iss. 5, pp. 168-179
Closed Access | Times Cited: 4
Assessment of cytotoxic properties of tetrahydroisoquinoline oximes in breast, prostate and glioblastoma cancer cells
Antonio Zandona, Matea Jurić, Ludovic Jean, et al.
Drug and Chemical Toxicology (2025), pp. 1-8
Closed Access
Detailed curriculum vitae of HER2-targeted therapy
Xiaonan Zhang, Ya Gao, Xi-Ya Zhang, et al.
Pharmacology & Therapeutics (2023) Vol. 245, pp. 108417-108417
Closed Access | Times Cited: 10
The therapeutic potential of natural metabolites in targeting endocrine-independent HER-2-negative breast cancer
Mirosława Püsküllüoğlu, Izabela Michalak
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Facile and Novel Synthetic Approach, Molecular Docking, Molecular Dynamics, and Drug‐Likeness Evaluation of 9‐Substituted Acridine Derivatives as Dual Anticancer and Antimicrobial Agents
Mohamed G. Abouelenein, Mahmoud Basseem I. Mohamed, Mohamed M. Elsenety, et al.
Chemistry & Biodiversity (2024) Vol. 21, Iss. 5
Closed Access | Times Cited: 3
Efficacy and safety of first‐line regimens for advanced HER2‐positive breast cancer: A Bayesian network meta‐analysis
Lixi Li, Yun Wu, Bo Lan, et al.
Cancer Innovation (2024) Vol. 3, Iss. 4
Open Access | Times Cited: 3
The Role of Tumor-Associated Antigen HER2/neu in Tumor Development and the Different Approaches for Using It in Treatment: Many Choices and Future Directions
Saleh Alrhmoun, С. В. Сенников
Cancers (2022) Vol. 14, Iss. 24, pp. 6173-6173
Open Access | Times Cited: 15
Inhibition of DPAGT1 suppresses HER2 shedding and trastuzumab resistance in human breast cancer
Muwen Yang, Li, Lingzhi Kong, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 14
Open Access | Times Cited: 8
Surface-Available HER2 Levels Alone Are Not Indicative of Cell Response to HER2-Targeted Antibody–Drug Conjugate Therapies
M. Scott Major, Christine S. Nervig, Annette Gerland, et al.
Pharmaceutics (2024) Vol. 16, Iss. 6, pp. 752-752
Open Access | Times Cited: 2
Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity
Yang Wang, Bing Xia, Lixia Cao, et al.
Antibody Therapeutics (2024) Vol. 7, Iss. 3, pp. 221-232
Open Access | Times Cited: 2
Discovery and Evaluation of TLR-Targeted Immune Agonists
Natalia Chernyak, Bhagyashree Bhagwat, Saraswathi Naravula, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 18, pp. 16222-16234
Closed Access | Times Cited: 2
Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases
Sanja Löb, Eva Linsmeier, Saskia-Laureen Herbert, et al.
Journal of Cancer Research and Clinical Oncology (2022) Vol. 149, Iss. 8, pp. 5417-5428
Open Access | Times Cited: 11
Trastuzumab-resistant breast cancer cells-derived tumor xenograft models exhibit distinct sensitivity to lapatinib treatment in vivo
Hao Liu, Sanbao Ruan, Margaret E. Larsen, et al.
Biological Procedures Online (2023) Vol. 25, Iss. 1
Open Access | Times Cited: 5
Targeting Breast Cancer: The Familiar, the Emerging, and the Uncharted Territories
Hamidreza Montazeri Aliabadi, Arthur Manda, Riya Sidgal, et al.
Biomolecules (2023) Vol. 13, Iss. 9, pp. 1306-1306
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top